


Curriculum Vitae

Name	Kohei Shitara	
Current Position & Affiliation	Chief of Department of Gastroenterology and Gastrointestinal Oncology	
Country	Japan	

Educational Background

1996-2002: Tohoku University School of Medicine
 M.D. degree awarded April, 2002 Japanese National Board: April 2002
 ECFMG Certificate : January 2005,

Professional Experience

April 2002-March 2004: Resident at Kameda Medical Hospital
 April 2004-May 2005: Senior Resident of gastroenterology at Kameda Medical Hospital
 June 2005-March 2008: Staff doctor of internal medicine and medical oncology at Misawa City Hospital
 April 2008-March 2012: Department of Clinical Oncology of Aichi Cancer Center Hospital
 April 2012-March 2013: Staff doctor of Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East
 April 2013-March 2017: Staff doctor of Department of Experimental Therapeutics and Gastrointestinal Oncology, National Cancer Center Hospital East
 March 2017-: Chief of Department of Gastrointestinal Oncology, National Cancer Center Hospital East

Professional Organizations

Guideline member of Japanese Gastric Cancer Association
 Active member of American Society of Clinical Oncology , Active member of European Society of Medical Oncology, Japanese Society of Internal Medicine, Japanese Society of Medical Oncology (JSMO) ,

Japanese Society of Clinical Oncology (JSCO), Japanese Gastric Cancer Association,
Japanese Clinical Oncology Group (JCOG), West Japanese Oncology Group (WJOG)
Faculty of World Congress on Gastrointestinal Cancer 2019
Members of the program committee of ASCO breakthrough meeting 2020-2022
ESMO faculty member for Gastrointestinal Tumors, non-Colorectal faculty group for
the period 2021-2025

Main Scientific Publications

1. Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Mansoor W, Braghiroli MI, Karaseva N, Caglevic C, Villanueva L, Goekkurt E, Satake H, Enzinger P, Alsina M, Benson A, Chao J, Ko AH, Wainberg ZA, Kher U, Shah S, Kang SP, Tabernero J. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. *JAMA Oncol.* 2020 Sep 3. doi: 10.1001/jamaoncol.2020.3370. Online ahead of print.
2. Kawazoe A, Fukuoka S, Nakamura Y, Kuboki Y, Wakabayashi M, Nomura S, Mikamoto Y, Shima H, Fujishiro N, Higuchi T, Sato A, Kuwata T, Shitara K (corresponding). Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. *Lancet Oncol.* 2020 Jun 23:S1470-2045(20)30271-0. doi: 10.1016/S1470-2045(20)30271-0. Online ahead of print.
3. Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee H, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, and Yamaguchi K. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. *N Engl J Med.* 2020 Jun 18;382(25):2419-2430. doi: 10.1056/NEJMoa2004413. Epub 2020 May 29.
4. Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M, Yoshii T, Kotani D, Tamura H, Mikamoto Y, Hirano N, Wakabayashi M, Nomura S, Sato A, Kuwata T, Togashi Y, Nishikawa H, Shitara K (corresponding). Regorafenib plus Nivolumab in Patients with Advanced Gastric or Colorectal Cancer: An Open-label, Dose-Escalation, and Dose-Expansion Phase 1b Trial (REGONIVO, EPOC1603). *J Clin Oncol.* 2020 Apr 28;JCO1903296. doi:10.1200/JCO.19.03296. [Epub ahead of print]

5. Shitara K, Satoh T, Iwasa S, Yamaguchi K, Muro K, Komatsu Y, Nishina T, Esaki T, Hasegawa J, Kakurai Y, Kamiyama E, Nakata T, Nakamura K, Sakaki H, Hyodo I. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors. *J Immunother Cancer*. 2019 Aug 14;7(1):219. doi: 10.1186/s40425-019-0679-9.
6. Shitara K, Ueha S, Shichino S, Aoki H, Ogiwara H, Nakatsura T, Suzuki T, Shimomura M, Yoshikawa T, Shoda K, Kitano S, Yamashita M, Nakayama T, Sato A, Kuroda S, Wakabayashi M, Nomura S, Yokochi S, Ito S, Matsushima K, Doi T. First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors. *J Immunother Cancer*. 2019 Jul 24;7(1):195. doi: 10.1186/s40425-019-0677-y.
7. Shitara K, Iwata H, Takahashi S, Tamura K, Park H, Modi S, Tsurutani J, Kadowaki S, Yamaguchi K, Iwasa S, Saito K, Fujisaki Y, Sugihara M, Shahidi J, Doi T. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. *Lancet Oncol*. 2019 Apr 29. pii: S1470-2045(19)30088-9. doi: 10.1016/S1470-2045(19)30088-9. [Epub ahead of print]
8. Shitara K, Yamanaka T, Denda T, Tsuji Y, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Yoshino T. REVERCE: A Randomized Phase II Study of Regorafenib Followed by Cetuximab Versus the Reverse Sequence for Previously Treated Metastatic Colorectal Cancer Patients. *Ann Oncol*. 2019 Feb 1;30(2):259-265. doi: 10.1093/annonc/mdy526.
9. Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Hosokawa A, Yalçın Ş, Fujitani K, Beretta GD, Cutsem EV, Winkler RE, Makris L, Ilson DH, Tabernero J. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2018 Oct 18. pii: S1470-2045(18)30739-3. doi: 10.1016/S1470-2045(18)30739-3. [Epub ahead of print] PMID: 30355453
10. Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. *Lancet*. 2018 Jul 14;392(10142):123-133. doi: 10.1016/S0140-6736(18)31257-1. PMID: 29880231